NorthWest Biotherapeutics Inc (NWBO)

[jondoeuk]

The US NCI published data from TIL trials in metastatic melanoma, with 194 patients treated. Among these, 63 (31%) had partial responses, and 46 (24%) had complete responses. Forty-four of 46 CR patients have remained in CR for over 14 to 152 months following a single treatment. With a median follow-up of 6.3 years, the estimated 10-year OS of all patients is approximately 35%, and the estimated 10-year OS of the 46 patients who achieved CR is over 90%. Also, addition data from the FDA https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.15_suppl.9508

This has been shown in other types, that is the depth of response correlates with survival (PFS and/or OS).